Insider Trading activities of Antigenics Inc /de/ insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Antigenics Inc /de/ since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Antigenics Inc /de/ since year 2005. Table 2 shows the detailed insider transactions of Antigenics Inc /de/ since 2005. The reporting company's ticker symbol is AGEN. The reporting company's CIK number is 1098972.
The total value of stock buying since 2005 is $9,040,963.
The total value of stock sales since 2005 is $22,632,729.
The total value of stock option exercises since 2005 is $224,502.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Antigenics Inc /de/ (AGEN).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-04 100,000 $334,508 0 $0 0 $0
2016-09 30,000 $188,700 0 $0 0 $0
2016-05 102,250 $324,875 0 $0 0 $0
2016-03 200,000 $805,599 0 $0 0 $0
2015-12 0 $0 219,576 $1,008,469 0 $0
2015-09 110,000 $553,500 0 $0 0 $0
2015-04 0 $0 1,107,377 $7,871,671 0 $0
2015-01 0 $0 2,343,630 $12,557,169 0 $0
2014-02 0 $0 5,000 $25,000 0 $0
2014-01 0 $0 2,850 $9,975 0 $0
2013-01 0 $0 288 $1,255 0 $0
2012-10 0 $0 288 $1,267 0 $0
2012-08 0 $0 288 $1,336 0 $0
2011-12 0 $0 57,995 $122,016 0 $0
2011-09 16,666 $49,764 0 $0 0 $0
2011-08 2,150,976 $1,096,997 0 $0 0 $0
2010-10 0 $0 10,665 $10,355 0 $0
2010-09 0 $0 8,151 $7,423 0 $0
2010-07 0 $0 8,185 $6,734 0 $0
2010-05 10,000 $13,400 0 $0 0 $0
2010-04 0 $0 8,615 $10,354 0 $0
2010-03 0 $0 116,667 $90,974 0 $0
2010-01 0 $0 338,821 $289,013 0 $0
2009-09 0 $0 3,786 $8,793 0 $0
2009-07 0 $0 268,327 $445,745 0 $0
2009-06 25,000 $49,250 25,000 $49,250 0 $0
2009-02 10,000 $3,700 0 $0 15,376 $0
2008-09 10,000 $17,130 0 $0 0 $0
2008-05 15,000 $35,340 0 $0 0 $0
2008-01 1,708,717 $5,126,151 0 $0 0 $0
2007-09 50,000 $116,550 0 $0 0 $0
2007-03 120,000 $228,999 0 $0 0 $0
2007-02 50,000 $96,500 50,000 $96,500 0 $0
2006-12 0 $0 5,000 $9,755 0 $0
2006-11 0 $0 4,500 $9,675 0 $0
2006-02 0 $0 0 $0 154,830 $224,502

Table 2. Detailed insider stock purchases, sales, and option exercises of Antigenics Inc /de/ insiders (AGEN)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-04-12 Armen Garo H (Chairman & CEO) Buy 29,456 3.29 97,057
2017-04-10 Armen Garo H (Chairman & CEO) Buy 70,544 3.37 237,451
2016-09-06 Wiinberg Ulf (Director) Buy 30,000 6.29 188,700
2016-05-09 Armen Garo H (Chairman & CEO) Buy 50,000 3.28 163,950
2016-05-05 Baysal Ozer (Chief Business Officer) Buy 2,250 3.10 6,975
2016-05-05 Armen Garo H (Chairman & CEO) Buy 50,000 3.08 153,950
2016-03-07 Armen Garo H (Chairman & CEO) Buy 200,000 4.03 805,599
2015-12-29 Armen Garo H (Chairman & CEO) Sale 85,224 4.57 389,644
2015-12-28 Armen Garo H (Chairman & CEO) Sale 134,352 4.61 618,825
2015-09-25 Ballantyne Charles Evan (Chief Financial Officer) Buy 10,000 5.05 50,500
2015-09-25 Armen Garo H (Chairman & CEO) Buy 100,000 5.03 503,000
2015-04-29 Malik Shahzad Sale 407,377 7.02 2,858,971
2015-04-28 Malik Shahzad Sale 700,000 7.16 5,012,700
2015-01-09 Qvt Fund V Lp (10% Owner) Sale 2,343,630 5.36 12,557,169
2014-02-26 Wentworth Kerry (VP, Clinical, Reg & Qual) Sale 5,000 5.00 25,000
2014-01-23 Valentine Karen (VP General Counsel) Sale 2,850 3.50 9,975
2013-01-30 Sharp Shalini (Director) Sale 288 4.36 1,255
2012-10-31 Sharp Shalini (Director) Sale 288 4.40 1,267
2012-08-29 Sharp Shalini (Director) Sale 288 4.64 1,336
2011-12-29 Valentine Karen (VP, General Counsel) Sale 7,605 1.98 15,057
2011-12-29 Wentworth Kerry (VP, Clinical, Reg, & Quality) Sale 8,939 2.01 17,967
2011-12-29 Klaskin Christine M (VP, Finance) Sale 6,391 2.00 12,782
2011-12-28 Valentine Karen (VP, General Counsel) Sale 1,301 2.09 2,719
2011-12-28 Sharp Shalini (CFO) Sale 1,711 2.09 3,575
2011-12-28 Wentworth Kerry (VP, Clinical, Reg, & Quality) Sale 1,893 2.09 3,956
2011-12-28 Klaskin Christine M (VP, Finance) Sale 1,095 2.09 2,288
2011-12-27 Valentine Karen (VP, General Counsel) Sale 2,169 2.14 4,641
2011-12-27 Sharp Shalini (CFO) Sale 2,853 2.14 6,105
2011-12-27 Wentworth Kerry (VP, Clinical, Reg, & Quality) Sale 3,156 2.14 6,753
2011-12-27 Klaskin Christine M (VP, Finance) Sale 1,824 2.14 3,903
2011-12-23 Valentine Karen (VP, General Counsel) Sale 608 2.20 1,335
2011-12-23 Sharp Shalini (CFO) Sale 795 2.20 1,746
2011-12-23 Wentworth Kerry (VP, Clinical, Reg, & Quality) Sale 886 2.20 1,946
2011-12-23 Klaskin Christine M (VP Finance) Sale 511 2.20 1,122
2011-12-22 Valentine Karen (VP, General Counsel) Sale 1,177 2.19 2,577
2011-12-22 Sharp Shalini (CFO) Sale 1,548 2.19 3,390
2011-12-22 Wentworth Kerry (VP, Clinical, Reg, & Quality) Sale 1,716 2.19 3,758
2011-12-22 Klaskin Christine M (VP Finance) Sale 993 2.19 2,174
2011-12-21 Valentine Karen (VP, General Counsel) Sale 2,348 2.24 5,254
2011-12-21 Sharp Shalini (CFO) Sale 3,087 2.24 6,908
2011-12-21 Wentworth Kerry (VP, Clinical, Reg, & Quality) Sale 3,414 2.24 7,640
2011-12-21 Klaskin Christine M (VP Finance) Sale 1,975 2.24 4,420
2011-09-30 Armen Garo H (Chairman & CEO) Buy 16,666 2.99 49,764
2011-08-16 Armen Garo H (Chairman & CEO) Buy 2,150,976 .51 1,096,997
2010-10-28 Sharp Shalini (CFO) Sale 1,500 .96 1,440
2010-10-27 Valentine Karen (VP and General Counsel) Sale 2,500 .98 2,450
2010-10-26 Wentworth Kerry (VP, Clin, Reg & Quality) Sale 4,165 .97 4,040
2010-10-26 Klaskin Christine M (VP, Finance) Sale 2,500 .97 2,425
2010-09-14 Valentine Karen (VP and General Counsel) Sale 3,333 .91 3,046
2010-09-14 Sharp Shalini (CFO) Sale 2,000 .91 1,824
2010-09-14 Wentworth Kerry (Vp, Clin, Reg & Quality) Sale 1,453 .91 1,314
2010-09-14 Klaskin Christine M (VP, Finance) Sale 1,365 .91 1,239
2010-07-27 Sharp Shalini (CFO) Sale 1,520 .93 1,407
2010-07-26 Wentworth Kerry (VP, Clin, Reg & Quality) Sale 4,165 .80 3,327
2010-07-26 Klaskin Christine M (VP, Finance) Sale 2,500 .80 2,000
2010-05-18 Wright Timothy (Director) Buy 10,000 1.34 13,400
2010-04-27 Sharp Shalini (CFO) Sale 1,950 1.16 2,262
2010-04-26 Wentworth Kerry (VP, Clin, Reg & Quality) Sale 4,165 1.22 5,060
2010-04-26 Klaskin Christine M (VP, Finance) Sale 2,500 1.21 3,032
2010-03-16 Valentine Karen (VP and General Counsel) Sale 29,039 .76 22,011
2010-03-11 Armen Garo H (Chairman & CEO) Sale 87,628 .79 68,963
2010-01-20 Valentine Karen (VP and General Counsel) Sale 93,789 .85 80,002
2010-01-20 Sharp Shalini (CFO) Sale 63,848 .85 54,462
2010-01-20 Wentworth Kerry (VP, Clin, Reg & Quality) Sale 102,316 .85 87,275
2010-01-20 Klaskin Christine M (VP, Finance) Sale 78,868 .85 67,274
2009-09-11 Valentine Karen (VP and General Counsel) Sale 1,094 2.32 2,541
2009-09-11 Wentworth Kerry (VP, Clin, Reg & Quality) Sale 1,367 2.32 3,175
2009-09-11 Klaskin Christine M (VP, Finance) Sale 1,325 2.32 3,077
2009-07-16 Valentine Karen (VP and General Counsel) Sale 15,930 1.62 25,774
2009-07-16 Sharp Shalini (CFO) Sale 32,525 1.62 52,625
2009-07-16 Wentworth Kerry (VP, Clin., Reg. & Qual.) Sale 20,302 1.62 32,848
2009-07-16 Klaskin Christine M (VP, Finance) Sale 19,905 1.62 32,206
2009-07-16 Armen Garo H (Chairman & CEO) Sale 99,683 1.62 161,287
2009-07-15 Valentine Karen (VP and General Counsel) Sale 7,753 1.76 13,668
2009-07-15 Sharp Shalini (CFO) Sale 13,271 1.76 23,396
2009-07-15 Wentworth Kerry (VP, Clin., Reg. & Qual.) Sale 13,271 1.76 23,396
2009-07-15 Klaskin Christine M (VP, Finance) Sale 7,672 1.76 13,525
2009-07-15 Armen Garo H (Chairman & CEO) Sale 38,015 1.76 67,020
2009-06-25 Wentworth Kerry (VP, Clin., Reg. and Qual.) Sale 25,000 1.97 49,250
2009-06-25 Armen Garo H (Chairman & CEO) Buy 25,000 1.97 49,250
2009-02-27 Levitsky Hyam (Director) Option Ex 15,376 .00 0
2009-02-25 Hatsopoulos John (Director) Buy 10,000 .37 3,700
2008-09-04 Hatsopoulos John (Director) Buy 3,000 1.72 5,160
2008-09-03 Hatsopoulos John (Director) Buy 7,000 1.71 11,970
2008-05-16 Margaret Eisen (Director) Buy 15,000 2.36 35,340
2008-01-09 Armen Garo H (Chairman and CEO) Buy 1,708,717 3.00 5,126,151
2007-09-14 Armen Garo H (Chairman and CEO) Buy 50,000 2.33 116,550
2007-03-15 Armen Garo H (Chairman and CEO) Buy 10,000 2.03 20,290
2007-03-14 Armen Garo H (Chairman and CEO) Buy 15,000 2.01 30,089
2007-03-13 Sharp Shalini (CFO) Buy 5,000 1.97 9,835
2007-03-13 Armen Garo H (Chairman and CEO) Buy 10,000 2.00 20,000
2007-03-12 Sharp Shalini (CFO) Buy 5,000 1.95 9,735
2007-03-12 Armen Garo H (Chairman and CEO) Buy 25,000 1.91 47,800
2007-03-09 Armen Garo H (Chairman and CEO) Buy 25,000 1.83 45,725
2007-03-08 Armen Garo H (Chairman and CEO) Buy 25,000 1.82 45,525
2007-02-09 Srivastava Pramod (Director) Sale 50,000 1.93 96,500
2007-02-09 Armen Garo H (CEO and Chairman of the Board) Buy 50,000 1.93 96,500
2006-12-14 Afeyan Noubar (Director) Sale 5,000 1.95 9,755
2006-11-02 Atlee Frank V Iii (Director) Sale 4,500 2.15 9,675
2006-02-28 Chadarevian Gamil De (Director) Option Ex 51,610 1.45 74,834
2006-02-23 Srivastava Pramod (Director) Option Ex 51,610 1.45 74,834
2006-02-22 Armen Garo H (CEO) Option Ex 51,610 1.45 74,834

Insider trading activities including stock purchases, stock sales, and option exercises of AGEN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Antigenics Inc /de/ (symbol AGEN, CIK number 1098972) see the Securities and Exchange Commission (SEC) website.